{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:42:48Z","timestamp":1791700968689,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T00:00:00Z","timestamp":1269561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T00:00:00Z","timestamp":1269561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/cgt.2010.7","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T13:17:19Z","timestamp":1269609439000},"page":"532-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Antisense HIF-1\u03b1 prevents acquired tumor resistance to angiostatin gene therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"X","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G W","family":"Krissansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,26]]},"reference":[{"key":"BFcgt20107_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J . Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182\u20131186.","journal-title":"N Engl J Med"},{"key":"BFcgt20107_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/37126","volume":"390","author":"T Boehm","year":"1997","unstructured":"Boehm T, Folkman J, Browder T, O'Reilly MS . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404\u2013407.","journal-title":"Nature"},{"key":"BFcgt20107_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2003.09.018","volume":"14","author":"Y Cao","year":"2004","unstructured":"Cao Y . Antiangiogenic cancer therapy. Semin Cancer Biol 2004; 14: 139\u2013145.","journal-title":"Semin Cancer Biol"},{"key":"BFcgt20107_CR4","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nbt1102-1067","volume":"20","author":"K Garber","year":"2002","unstructured":"Garber K . Angiogenesis inhibitors suffer new setback. Nat Biotechnol 2002; 20: 1067\u20131068.","journal-title":"Nat Biotechnol"},{"key":"BFcgt20107_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumours. Cancer Cell 2005; 8: 299\u2013309.","journal-title":"Cancer Cell"},{"key":"BFcgt20107_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdi118","volume":"16","author":"J Drevs","year":"2005","unstructured":"Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L et al. Soluble markers for the assessment of biological activity with PTK787\/ZK 222584 (PTK\/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005; 16: 558\u2013565.","journal-title":"Ann Oncol"},{"key":"BFcgt20107_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16\u201324.","journal-title":"J Clin Oncol"},{"key":"BFcgt20107_CR8","first-page":"526","volume":"61","author":"I Ding","year":"2001","unstructured":"Ding I, Sun JZ, Fenton B, Liu WM, Kimsely P, Okunieff P et al. Intratumoural administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res 2001; 61: 526\u2013531.","journal-title":"Cancer Res"},{"key":"BFcgt20107_CR9","doi-asserted-by":"publisher","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","volume":"23","author":"CG Willett","year":"2005","unstructured":"Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23: 8136\u20138139.","journal-title":"J Clin Oncol"},{"issue":"2A","key":"BFcgt20107_CR10","first-page":"1159","volume":"23","author":"J Drevs","year":"2003","unstructured":"Drevs J . Soluble markers for the detection of hypoxia under antiangiogenic treatment. Anticancer Res 2003; 23 (2A): 1159\u20131161.","journal-title":"Anticancer Res"},{"key":"BFcgt20107_CR11","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","volume":"64","author":"G Bocci","year":"2004","unstructured":"Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 2004; 64: 6616\u20136625.","journal-title":"Cancer Res"},{"key":"BFcgt20107_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-2004-822973","volume":"30","author":"Y Cao","year":"2004","unstructured":"Cao Y, Xue L . Angiostatin. Semin Thromb Hemost 2004; 30: 83\u201393.","journal-title":"Semin Thromb Hemost"},{"key":"BFcgt20107_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","volume":"79","author":"MS O'Reilly","year":"1994","unstructured":"O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315\u2013328.","journal-title":"Cell"},{"key":"BFcgt20107_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nm0696-689","volume":"2","author":"MS O'Reilly","year":"1996","unstructured":"O'Reilly MS, Holmgren L, Chen C, Folkman J . Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat Med 1996; 2: 689\u2013692.","journal-title":"Nat Med"},{"key":"BFcgt20107_CR15","first-page":"4025","volume":"9","author":"LV Beerepoot","year":"2003","unstructured":"Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, Sidor C et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res 2003; 9: 4025\u20134033.","journal-title":"Clin Cancer Res"},{"key":"BFcgt20107_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/sj.cgt.7700639","volume":"10","author":"JM Joseph","year":"2003","unstructured":"Joseph JM, Bouquet C, Opolon P, Morizet J, Aubert G, R\u00f6ssler J et al. High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts. Cancer Gene Ther 2003; 10: 859\u2013866.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt20107_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.gt.3301703","volume":"9","author":"S Indraccolo","year":"2002","unstructured":"Indraccolo S, Gola E, Rosato A, Minuzzo S, Habeler W, Tisato V et al. Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Therapy 2002; 9: 867\u2013878.","journal-title":"Gene Therapy"},{"key":"BFcgt20107_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0167-8140(03)00011-2","volume":"67","author":"J Bussink","year":"2003","unstructured":"Bussink J, Kaanders JH, van der Kogel AJ . Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003; 67: 3\u201315.","journal-title":"Radiother Oncol"},{"key":"BFcgt20107_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL . Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"BFcgt20107_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/mi.2.4.229","volume":"2","author":"AO Fedele","year":"2002","unstructured":"Fedele AO, Whitelaw ML, Peet DJ . Regulation of gene expression by the hypoxia-inducible factors. Mol Interv 2002; 2: 229\u2013243.","journal-title":"Mol Interv"},{"key":"BFcgt20107_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.1147949","volume":"318","author":"GL Semenza","year":"2007","unstructured":"Semenza GL . Life with oxygen. Science 2007; 318: 62\u201364.","journal-title":"Science"},{"key":"BFcgt20107_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4161\/cc.6.7.4084","volume":"6","author":"S Fulda","year":"2007","unstructured":"Fulda S, Debatin KM . HIF-1-regulated glucose metabolism: a key to apoptosis resistance? Cell Cycle 2007; 6: 790\u2013792.","journal-title":"Cell Cycle"},{"key":"BFcgt20107_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"M Hockel","year":"2001","unstructured":"Hockel M, Vaupel P . Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266\u2013276.","journal-title":"J Natl Cancer Inst"},{"key":"BFcgt20107_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/sj.gt.3301388","volume":"8","author":"X Sun","year":"2001","unstructured":"Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW . Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy 2001; 8: 638\u2013645.","journal-title":"Gene Therapy"},{"key":"BFcgt20107_CR25","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/j.1349-7006.2008.00905.x","volume":"99","author":"F Liu","year":"2008","unstructured":"Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H et al. Antisense hypoxia-inducible factor 1\u03b1 gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinomas. Cancer Sci 2008; 99: 2055\u20132061.","journal-title":"Cancer Sci"},{"key":"BFcgt20107_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/hum.2008.164","volume":"20","author":"X Sun","year":"2009","unstructured":"Sun X, Jiang H, Jiang X, Tan H, Meng Q, Sun B et al. Downregulating hypoxia-inducible factor 1 augments transcatheter arterial embolization to treat hepatocellular carcinomas in rats. Hum Gene Ther 2009; 20: 314\u2013324.","journal-title":"Hum Gene Ther"},{"key":"BFcgt20107_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/sj.cgt.7700370","volume":"8","author":"X Sun","year":"2001","unstructured":"Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW . Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther 2001; 8: 719\u2013727.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt20107_CR28","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1097\/PAS.0b013e318094fed8","volume":"31","author":"C Di Cristofano","year":"2007","unstructured":"Di Cristofano C, Minervini A, Menicagli M, Salinitri G, Bertacca G, Pefanis G et al. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. Am J Surg Pathol 2007; 31: 1875\u20131881.","journal-title":"Am J Surg Pathol"},{"key":"BFcgt20107_CR29","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nbt1323","volume":"25","author":"F Shojaei","year":"2007","unstructured":"Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25: 911\u2013920.","journal-title":"Nat Biotechnol"},{"key":"BFcgt20107_CR30","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1158\/1078-0432.CCR-07-0111","volume":"13","author":"Y Mizukami","year":"2007","unstructured":"Mizukami Y, Kohgo Y, Chung DC . Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007; 13: 5670\u20135674.","journal-title":"Clin Cancer Res"},{"key":"BFcgt20107_CR31","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/0008-5472.CAN-03-3017","volume":"64","author":"Y Mizukami","year":"2004","unstructured":"Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC . Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004; 64: 1765\u20131772.","journal-title":"Cancer Res"},{"key":"BFcgt20107_CR32","first-page":"8890","volume":"63","author":"A Abdollahi","year":"2003","unstructured":"Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003; 63: 8890\u20138898.","journal-title":"Cancer Res"},{"key":"BFcgt20107_CR33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/sj.bjc.6603694","volume":"96","author":"P Hinnen","year":"2007","unstructured":"Hinnen P, Eskens FA . Vascular disrupting agents in clinical development. Br J Cancer 2007; 96: 1159\u20131165.","journal-title":"Br J Cancer"},{"key":"BFcgt20107_CR34","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.emboj.7600196","volume":"23","author":"M Koshiji","year":"2004","unstructured":"Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE . HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23: 1949\u20131956.","journal-title":"EMBO J"},{"key":"BFcgt20107_CR35","doi-asserted-by":"publisher","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-05-1235","volume":"65","author":"D Kong","year":"2005","unstructured":"Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005; 65: 9047\u20139055.","journal-title":"Cancer Res"},{"key":"BFcgt20107_CR36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.605.65.2","volume":"65","author":"C Tan","year":"2005","unstructured":"Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 2005; 65: 605\u2013612.","journal-title":"Cancer Res"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt20107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt20107","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt20107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T10:09:56Z","timestamp":1711361396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt20107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,26]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["BFcgt20107"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2010.7","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,26]]},"assertion":[{"value":"7 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}